Nektr Technologies has Completed its Phase II/III Pharmaceutical clinical trial against the European market leader with outstanding results.
Nektrs breakthrough Technology, Mycosinate® has succeeded in outperforming the European market leader by over 5x in reducing infected area of the nail.
The prevalence of Onychomycosis, commonly known as fungal nail infection, increases steadily with age and is present in 50-60% of people over the age of 60 . This condition is caused by the dermatophyte Trichophyton rubrum and associated pathogens.
Present fungal nail treatments are broadly ineffective. due to a number of factors Mycosinate® with its low molecular weight has demonstrated a very successful pathway to deliver the lethal payload to the source of the infection.
Figure 1: Difference between Treatment A (Mycosinate) and Treatment B (5% Amorolfine) in percentage change in clear healthy nail area.
Figure 2: Difference between Treatment A (Mycosinate) and Treatment B (5% Amorolfine) in percentage change of infected nail area
Figure 3: Mycosinate average area of infection trends
Pharmaceutical Development Pathway
Get in touch
Do you have questions about Nektr or our technology? Connect with us using the details below or get in touch by filling out the form We would be happy to answer your questions!
Finisklin Business & Technology Park,
Sligo, Ireland, F91 HF66